TrialThe Lancet. Infectious diseases2025

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.